tradingkey.logo

Precigen Inc

PGEN
4.290USD
+0.050+1.18%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
1.52BValor de mercado
PerdaP/L TTM

Mais detalhes de Precigen Inc Empresa

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Informações de Precigen Inc

Código da empresaPGEN
Nome da EmpresaPrecigen Inc
Data de listagemAug 08, 2013
CEOSabzevari (Helen)
Número de funcionários143
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 08
Endereço20374 Seneca Meadows Parkway
CidadeGERMANTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20876
Telefone13015569900
Sitehttps://precigen.com/
Código da empresaPGEN
Data de listagemAug 08, 2013
CEOSabzevari (Helen)

Executivos da empresa Precigen Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+557913.00%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+123618.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+116147.00%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+123331.00%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+123618.00%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
217.84K
+15000.00%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
110.60K
-235467.00%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
65.03K
+6000.00%
Mr. Randal Joe Kirk
Mr. Randal Joe Kirk
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+557913.00%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+123618.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+116147.00%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+123331.00%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+123618.00%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
217.84K
+15000.00%

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Collaborationandlicensingagreements
1.82M
62.22%
Service
942.00K
32.24%
Product
162.00K
5.54%
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Collaborationandlicensingagreements
1.82M
62.22%
Service
942.00K
32.24%
Product
162.00K
5.54%

Distribuição de ações

Atualizado em: seg, 17 de nov
Atualizado em: seg, 17 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Third Security, LLC
35.03%
Patient Capital Management, LLC
7.48%
Merck Serono SA
5.84%
Point72 Asset Management, L.P.
5.17%
William H. Miller III Living Trust
4.91%
Outro
41.57%
Investidores
Investidores
Proporção
Third Security, LLC
35.03%
Patient Capital Management, LLC
7.48%
Merck Serono SA
5.84%
Point72 Asset Management, L.P.
5.17%
William H. Miller III Living Trust
4.91%
Outro
41.57%
Tipos de investidores
Investidores
Proporção
Venture Capital
35.04%
Investment Advisor
16.54%
Hedge Fund
12.13%
Individual Investor
7.79%
Investment Advisor/Hedge Fund
6.56%
Corporation
5.84%
Research Firm
1.50%
Pension Fund
0.11%
Bank and Trust
0.07%
Outro
14.44%

Participação acionária institucional

Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
319
238.99M
67.55%
+20.23M
2025Q3
286
222.21M
62.96%
+17.23M
2025Q2
298
229.52M
77.76%
-784.34K
2025Q1
334
228.75M
77.50%
-12.95M
2024Q4
336
223.34M
76.44%
-15.36M
2024Q3
342
222.44M
77.88%
+21.14M
2024Q2
350
183.56M
71.33%
-22.34M
2024Q1
356
187.95M
73.95%
-17.15M
2023Q4
369
187.18M
73.43%
-12.81M
2023Q3
377
185.65M
75.06%
-11.67M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Third Security, LLC
123.95M
35.03%
-4.78M
-3.71%
Nov 21, 2025
Patient Capital Management, LLC
26.46M
7.48%
+10.19M
+62.65%
Sep 30, 2025
Merck Serono SA
20.65M
5.84%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
2.74M
0.77%
+2.74M
--
Sep 30, 2025
William H. Miller III Living Trust
17.39M
4.91%
+17.39M
--
Jun 26, 2025
Tang Capital Management, LLC
12.40M
3.5%
+12.40M
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
10.74M
3.03%
+905.62K
+9.21%
Sep 30, 2025
The Vanguard Group, Inc.
8.94M
2.53%
-127.74K
-1.41%
Sep 30, 2025
State Street Investment Management (US)
4.49M
1.27%
+1.46M
+48.22%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.85M
1.09%
+99.56K
+2.66%
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Inspire Small/Mid Cap ESG ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.14%
iShares Micro-Cap ETF
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
State Street SPDR S&P Biotech ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
ProShares UltraPro Russell2000
0.02%
Ver Mais
Inspire Small/Mid Cap ESG ETF
Proporção0.24%
ProShares Ultra Nasdaq Biotechnology
Proporção0.14%
iShares Micro-Cap ETF
Proporção0.12%
Invesco Nasdaq Biotechnology ETF
Proporção0.12%
State Street SPDR S&P Biotech ETF
Proporção0.11%
Vanguard US Momentum Factor ETF
Proporção0.1%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.06%
iShares Biotechnology ETF
Proporção0.05%
iShares Russell 2000 Growth ETF
Proporção0.03%
ProShares UltraPro Russell2000
Proporção0.02%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI